AmgenFRA:AMG +2.20%87 Interest Coverage is 4.06 as of Mar. 2026, which is 42% below its 10-year median of 7.02. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €308.97 (Fairly Valued). The stock has 7 warning signs investors should review. Among 685 Drug Manufacturers companies, Amgen ranks worse than 74.89% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Amgen's
Operating Income
for the
three
months ended in Mar. 2026 was €2,306 Mil. Amgen's Interest Expense for the
three
months ended in Mar. 2026 was €-568 Mil.
Amgen's interest coverage for the quarter that ended in Mar. 2026 was 4.06.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Amgen's Interest Coverage or its related term are showing as below:
FRA:AMG'
s Interest Coverage Range Over the Past 10 Years
Min: 2.3 Med: 7.02 Max: 7.77
Current: 3.93
FRA:AMG's Interest Coverage is ranked worse than 74.89% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs FRA:AMG: 3.93
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Amgen Interest Coverage Related Terms
Amgen Interest Coverage Historical Data
* Premium members only.
The historical data trend for Amgen's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:AMG vs GILD, PFE, BMY: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Amgen's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Amgen's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (FRA:AMG) has a Interest Coverage of 4.06 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amgen and its competitors. This is 42% below median its historical median of 7.02. Over the past decade, Amgen's Interest Coverage has ranged from 2.30 to 7.77. According to the industry distribution chart, Amgen ranks #513 out of 685 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Amgen's Interest Coverage too high?
Amgen's current Interest Coverage of 4.06 is 42% below median its 10-year median of 7.02. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 7.77. The Drug Manufacturers industry median Interest Coverage is 12.78. Amgen's value of 4.06 is 68.2% below this industry median. Based on the distribution chart, Amgen ranks #513 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Interest Coverage compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #513 out of 685 companies for Interest Coverage. This places Amgen in the lower half of its industry. The industry median Interest Coverage is 12.78. Amgen's value of 4.06 is 68.2% below this benchmark. Historically, Amgen's own Interest Coverage has ranged from 2.30 to 7.77 over the past decade. While the company's 10-year median is 7.02 vs. the industry median of 12.78, Amgen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Interest Coverage of 4.06 is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Interest Coverage is 4.06, which is 42% below median its own 10-year median of 7.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.97, compared to a current price of €313.15 — trading 1.4% above its estimated fair value. The current Interest Coverage is 4.06, which is 42% below median its 10-year median of 7.02 and 68.2% below the Drug Manufacturers industry median of 12.78. Amgen's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Interest Coverage is 4.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (FRA:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €313.15 is trading 1.4% above its estimated GF Value™ of €308.97.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for FRA:AMG:
Interest Coverage: 4.06 (42% below median its 10-year median of 7.02)
GF Value™: €308.97 vs. price of €313.15 (1.4% above fair value)
Industry Position: 68.2% below the Drug Manufacturers median (#513 of 685)
No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for FRA:AMG
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AMG has been successfully added to your 
